Research programme: tuberculosis therapies - ChemDiv/Chemical Diversity Research Institute
Latest Information Update: 10 Oct 2011
At a glance
- Originator ChemDiv; Chemical Diversity Research Institute; Novartis Institute for Tropical Diseases
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 06 Oct 2011 Chemical Diversity Research Institute enters collaboration and License Option Agreement with Novartis Institute for Tropical Diseases for this research programme
- 06 Oct 2011 Preclinical trials in Tuberculosis in Singapore (unspecified route)
- 15 Apr 2009 Preclinical development is ongoing in Russia